Our findings suggest that cabotegravir is much more effective than Truvada in preventing HIV infection in women.
- Associate Professor and Director: Research at the Wits Reproductive Health and HIV Institute I, University of the Witwatersrand
South Africa’s data rollout of its pre-exposure prophylaxis shows that there is a relatively slow, but increasing, uptake. However, more needs to be done to target young women.
Young women in southern Africa are most at risk of becoming infected with HIV. If they take a pre-exposure prophylaxis like Truvada it could change their lives.
With nearly one-fifth of the globe’s HIV positive population, South Africa has the largest anti-retroviral program in the world. But HIV prevention still presents a big challenge for the country.
Contact Sinead for
- General
- Media request
- Speaking request
- Consulting / Advising
- Research collaboration
- Research supervision
- Location: Johannesburg, South Africa
- Article Feed
-
- Joined
